Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS SOUTH AUSTRALIA INC

Registered Charity 3104

Email:
sacfs@sacfs.asn.au

Mailing address:

PO Box 322,
Modbury,
South Australia 5092

Phone:
1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm
(phone)

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (PDF, 156KB)
Why become a member?

Pharmaceutical Interventions In Chronic Fatigue Syndrome: A Literature-Based Commentary

Sunday 17 March 2019

 

From the medical journal Clinical Therapeutics:

 

Drugs
 

Pharmaceutical Interventions in Chronic Fatigue Syndrome: A Literature-based Commentary

Spencer Richman B.Sc.,
Matthew C. Morris Ph.D.,
Gordon Broderick Ph.D.,
Travis J.A. Craddock Ph.D.,
Nancy G. Klimas M.D.,
Mary Ann Fletcher Ph.D.
https://doi.org/10.1016/j.clinthera.2019.02.011
Available online 11 March 2019
© 2019 Published by Elsevier Inc.

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disorder characterized by prolonged periods of fatigue, chronic pain, depression, and a complex constellation of other symptoms.

Currently, ME/CFS has no known cause, nor are the mechanisms of illness well understood.

Therefore, with few exceptions, attempts to treat ME/CFS have been directed mainly toward symptom management.

These treatments include antivirals, pain relievers, antidepressants, and oncologic agents as well as other single-intervention treatments. Results of these trials have been largely inconclusive and, in some cases, contradictory.

Contributing factors include a lack of well-designed and -executed studies and the highly heterogeneous nature of ME/CFS, which has made a single etiology difficult to define.

Because the majority of single-intervention treatments have shown little efficacy, it may instead be beneficial to explore broader-acting combination therapies in which a more focused precision-medicine approach is supported by a systems-level analysis of endocrine and immune co-regulation.

Keywords

ME/CFS; clinical trials; immune therapy; illness heterogeneity; precision medicine

 

Full article…

 


 

blog comments powered by Disqus
Previous Previous Page